🚗 🚙 Turn your trusty old car into trustworthy journalism Learn more

Health care tops list of voters' economic worries

Feb 22, 2024
While inflation is moderating, some health-related costs are still climbing.
Health care affordability and inflation are top concerns for voters this year.
Alex Wong/Getty Images

Medicare to start negotiating prices for 10 drugs in 2024

Dec 29, 2023
But drug companies are trying to stymie the effort with a raft of lawsuits.
Medicare’s ability to negotiate drug prices will apply to just 10 medications for now, including treatments for heart disease and diabetes.
stevecoleimages/Getty Images

Who will end up paying the price for Biogen's new Alzheimer's drug?

Jun 18, 2021
The cost of the newly approved treatment will be about $56,000 a year, much of it paid for by Medicare.
Biogen’s new Alzheimer's treatment drug, Aduhelm, has an annual sticker price of $56,000.
Dominick Reuter/AFP via Getty Images

Cancer death rates have fallen 27 percent

Jan 9, 2019
Oncology experts say advances in cancer drugs have played a major role.
Cathy Bradley says many cancer patients stay at work because they need the health insurance their employer provides.
Justin Sullivan/Getty Images

Deals aimed at reining in costs of cancer drugs show promise

Jun 6, 2016
Some manufacturers are willing to tie drug price to performance.
Dr. Julie Brahmer (R) and Katie Thornton review PET (Positron Emission Tomography) scans of a patient being treated at the Kimmel Comprehensive Cancer Center at Johns Hopkins in Baltimore, Maryland. 
Win McNamee/Getty Images

Cigna deal calls for rebates if drugs don't perform

May 11, 2016
It's the seventh such deal for the insurance giant, which is putting pressure on drug makers in an effort to keep costs down.
Rosemary Petty, a Publix Supermarket pharmacy technician, counts out a prescription August 7, 2007 in Miami, Florida. 
Joe Raedle/Getty Images

FTC fights against new strategy for delaying generics

Apr 1, 2016
FTC files case against drug maker for deals cut with two generic firms that extend its monopoly
John Moore/Getty Images

For public good, not for profit.

Why rare-disease treatments can be big business

Jan 11, 2016
Combined, Shire and Baxalta expect 65 percent of total revenue to come from rare disease treatments.

Police turn to pricey rehab drug for offenders

Nov 4, 2015
The drug, administered once a month, helps ensure patient compliance.

Valeant: how aggressively can a drug company sell

Oct 30, 2015
Valeant is under scrutiny for its business practices.